BACKGROUND: This study was conducted to evaluate the efficacy and safety of @entity1311 - @entity3003 combined with intercalated @entity4562 in @entity1 with advanced, untreated, nonsquamous @entity1149 . METHODS: A total of 29 @entity1 were enrolled in the study. All @entity1 were Chinese, with a histology type of @entity420 , without a smoking history, and as a result of the limited tissue sample, an @entity470 ( @entity470 ) mutation test could not be performed. All @entity1 received chemotherapy of @entity1311 - @entity3003 every 21 days for four cycles, and @entity4562 (250   mg/day) was administered on days eight to 17 of the chemotherapy cycle. If the @entity1 responded to chemotherapy, maintenance therapy of 250mg of @entity4562 could be administered daily. RESULTS: All of the 29 @entity1 received at least one cycle of chemotherapy and @entity4562 , and 25 @entity1 received four cycles of therapy. Eighteen @entity1 selected maintenance therapy with @entity4562 . The objective response rate was 74.1% (95% confidence interval, 53.7% to 88.9%). No complete response was achieved. The median progression-free survival was 16 months, however, the median overall survival was not available by the conclusion of the study. The major adverse event was @entity1503 . CONCLUSIONS: The regimen of @entity1311 - @entity3003 combined with intercalated @entity4562 showed a high response rate and a favorable safety profile. @entity4562 maintenance therapy was proven to be beneficial. This study proposes a good pattern of chemotherapy combined with @entity470 @entity4149 kinase inhibitors.

Phase II trial of @entity1311 - @entity3003 with intercalated XXXX for untreated, @entity470 gene mutation status unknown @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib', 'Gefitinib'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity4562 :: (MESH:C419708,Chemical) :: ['gefitinib']
